Poxel S.A. (EPA:POXEL)
0.4300
-0.0030 (-0.69%)
Apr 16, 2025, 10:33 AM CET
Poxel Employees
Poxel had 6 employees as of December 31, 2023. The number of employees decreased by 31 or -83.78% compared to the previous year.
Employees
6
Change (1Y)
-31
Growth (1Y)
-83.78%
Revenue / Employee
€364,667
Profits / Employee
€2,684,167
Market Cap
23.24M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
EssilorLuxottica Société anonyme | 153,498 |
Sanofi | 82,878 |
Sartorius Stedim Biotech | 9,901 |
bioMérieux | 14,754 |
Eurofins Scientific SE | 62,696 |
Ipsen | 5,358 |
Virbac | 5,620 |
emeis Société anonyme | 77,954 |
Poxel News
- 26 days ago - Poxel Announces Positive Results from a Preclinical Study for PXL065, a Proprietary Deuterium-Stabilized R-Stereoisomer of Pioglitazone, in Hypertrophic Cardiomyopathy - Business Wire
- 3 months ago - Poxel to receive sales-based payment and higher level of royalties from Sumitomo Pharma in Q1 2025 for TWYMEEG® Achieving JPY 5 billion Net Sales in Japan - Business Wire
- 5 months ago - Poxel Announces that its Annual General Meeting Will Be Held on November 28, 2024, at 9 am CET and the Availability of Preparatory Documents - Business Wire
- 6 months ago - Poxel SA (STU:7PO) Full Year 2023 Earnings Call Highlights: Strategic Moves and Financial Challenges - GuruFocus
- 6 months ago - Poxel Reports Financial Results for Full Year 2023 and Provides Corporate Update - Business Wire
- 7 months ago - Poxel Announces Agreement with OrbiMed to Monetize a portion of TWYMEEG® Royalties for USD 50 million - Business Wire
- 7 months ago - Poxel Reports Revenue for the Second Quarter and First Half 2024 and Provides Corporate Update - Business Wire
- 9 months ago - Sumitomo Pharma and Poxel Announce Topline Results from Post-Marketing Clinical Study on TWYMEEG® for the Treatment of Type 2 Diabetes in Japan - Business Wire